IRSB On Other Exchanges
text size: T | T
Back to Snapshot
Company Description

Contact Info

5201 Great America Parkway

Suite 320

Santa Clara, CA 95054

United States

Phone: 408-867-2885

Fax: 408-867-5068

Iris BioTechnologies Inc., a life sciences company, engages in developing solutions for the detection and monitoring of monogenic and complex genomic diseases. In 2014, the company formed Iris Wellness Labs, Inc. for the purpose of developing certain business lines. The company offers Health Passport in its BioWindows 2.0 Informatics System. Health Passport is a HIPAA compliant, Web based medical information storage system that allows participants to grant sharing capabilities of their confidential medical and lifestyle information to physicians and/or family members anywhere in the world. This allows families to build multi-generational medical family trees that would help assure that they receive more personalized care. The information within the BioWindows System would be used to optimize the choice of medical treatment and also to develop personalized and targeted drugs with maximum efficacy and minimal side effects. The company has developed a manufacturing system with the capabilities to produce various Nano-biochips with a choice of messenger ribonucleic acids (RNAs), microRNAs, proteins, or other biomarker probes for the diagnosis and prognosis of breast cancer, colon cancer, and various other diseases. The company’s Nano-biochip manufacturing and usage tracking process has been tested with 2D and 1D barcode scanners on both labeled and stamped products in conjunction with touch screen functions, and the company has streamlined the automated patient sample processing protocols. The company has explored collaborating with various entities in the U.S. and internationally to begin clinical research studies to determine the effectiveness of tissue genetic testing in patients undergoing surgery for breast cancer. The company’s biochip technology is expected to advance personalized medicine, improving a physician’s ability to match cancer treatment plans to genetic indicators. The company has the capability to launch the clinical BreastCancerChip through the Clinical Laboratory Improvement Amendments of 1988 (CLIA) laboratory certification without the U.S. Food and Drug Administration (FDA) approval, similar to the Oncotype Dx test offered by Genomic Health Inc. (Genomic Health). With FDA approval, all of the company’s tests could be performed in any certified laboratory. The Iris BioWindows Informatics System for Personalized and Targeted Medicine handles the analysis of the gene expression and genetic variation data, as well as protein and other biomarker information collected by the Nano-Biochip. BioWindows is an artificial intelligence system, which includes a database with molecular signatures, in-depth patient demographics and lifestyle information, family medical histories and treatment-response profiles for various diseases. The company’s Nano-Biochips are special silicon chips with multiple functions. Solution The company’s nano-biochip technology platform is developed using a convergence of scientific disciplines in nanotechnology, semiconductor manufacturing, microfluidics, chemistry, molecular biology, genetics, genomics, and information technology. The company’s technology platform includes a combination of oligonucleotide, peptide nucleic acid (PNA) probes with binding affinity and specificity that are the ideal length and highly purified, protein biomarkers, and other molecules; a proprietary binding system to secure probes to a soft metal chip surface; controlled probe spacing and chip surface design to improve sensitivity; microfluidics and the use of paramagnetic labels with a magnetic field to improve hybridization speed; a chip design and manufacturing process; use of robotics for precise automated chip manufacturing; and an information technology system based on proprietary algorithms for analysis, correlation and classification of test results. Microfluidics deals with the precise control and manipulation of microliter and nanoliter volumes of fluids. The company is also developing other new technologies. Single cell genomics and proteomics, DNA editing, nano-particle applications, circulating tumor cell analysis, cell free DNA, stem cell therapy, microbiome modificati


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

IRSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IRSB.
View Industry Companies

Industry Analysis


Industry Average

Valuation IRSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IRIS BIOTECHNOLOGIES INC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at